1. (Invited) Potential and Activities of III-V/Si Tandem Solar Cells. (10th September 2015) Authors: Yamaguchi, Masafumi; Lee, K-H; Araki, K; Kojima, N; Ohshita, Y Journal: ECS transactions Issue: Volume 69:Number 4(2015) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 150OAtezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study. (25th November 2018) Authors: Lee, K-H; Hsu, C-H; Lee, M S; Ryoo, B-Y; Verret, W; He, A R; Kwan, A; Liu, B; Iizuka, K; Stein, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 200PLiposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study. (25th November 2018) Authors: Chen, L-T; Macarulla Mercadé, T; Lee, K-H; Lakatos, G; Wang-Gillam, A; Mirakhur, B; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 38OTalazoparib (TALA) vs physician's choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA. (24th November 2019) Authors: Lee, K-H; Kim, S-B; Sohn, J; Goodwin, A; Usari, T; Lanzalone, S; Im, Y-H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. (17th December 2018) Authors: Deva, S; Lee, J-S; Lin, C-C; Yen, C-J; Millward, M; Chao, Y; Keam, B; Jameson, M; Hou, M-M; Kang, Y-K; Markman, B; Lu, C-H; Rau, K-M; Lee, K-H; Horvath, L; Friedlander, M; Hill, A; Wu, J; Hou, J; Desai, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 733PNAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). (23rd October 2018) Authors: Macarulla Mercade, T; Bodoky, G; Siveke, J; Lee, K-H; Chen, J; Mirakhur, B; Dean, A; Chen, L-T; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 759PPhase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer. (23rd October 2018) Authors: Yoon, J S; Lee, K-H; Cheon, G J; Bang, Y-J; Oh, D-Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Characteristic features of unruptured intracranial aneurysms: predictive risk factors for aneurysm rupture. Issue 5 (2nd September 2009) Authors: You, S-H; Kong, D-S; Kim, J-S; Jeon, P; Kim, K H; Roh, H K; Kim, G-M; Lee, K-H; Hong, S-C Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 81:Issue 5(2010) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Evidence of thalamic disinhibition in patients with hemichorea: semiquantitative analysis using SPECT. Issue 3 (1st March 2002) Authors: Kim, J-S; Lee, K-S; Lee, K-H; Kim, Y-I; Kim, B-S; Chung, Y-A; Chung, S-K Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 72:Issue 3(2002) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Pishvaian, M J; Lee, M S; Ryoo, B-Y; Stein, S; Lee, K-H; Verret, W; Spahn, J; Shao, H; Liu, B; Iizuka, K; Hsu, C-H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗